口服米索前列醇联合Foley球囊引产:整群随机试验
该整群随机试验纳入孕37周及以上、宫颈扩张≤2 cm、胎膜完整的引产孕妇,比较口服米索前列醇前放置Foley球囊与单用口服米索前列醇的效果。结果显示两组首次引产阴道分娩率无差异(78% vs 77%),但联合组临床绒毛膜羊膜炎发生率更高(18% vs 14%)。
要点
- 联合Foley球囊未提高首次引产阴道分娩率。
- 联合Foley球囊增加临床绒毛膜羊膜炎风险。
- 新生儿结局两组无差异。
核心结论
- 对于足月、胎膜完整孕妇,口服米索前列醇前放置Foley球囊不增加阴道分娩率,反而增加临床绒毛膜羊膜炎。
主要发现
- 首次引产阴道分娩率联合组78%,单药组77%(RR 1.00;95%CI 0.96-1.05;aRR 1.00;95%CI 0.95-1.05)。
- 临床绒毛膜羊膜炎联合组18%,单药组14%(RR 1.30;95%CI 1.07-1.58;aRR 1.30;95%CI 1.08-1.56)。
- 新生儿结局两组无差异。
关键数值与推荐
- 纳入标准:孕37周及以上、宫颈扩张≤2 cm、胎膜完整、有引产指征。
- 干预:Foley球囊放置后口服米索前列醇100微克,或单用口服米索前列醇100微克。
- 主要结局:首次引产尝试的阴道分娩。
临床怎么用
- 不推荐在口服米索前列醇引产常规联合Foley球囊以图提高阴道分娩率。
- 联合方案需警惕临床绒毛膜羊膜炎风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether the induction of labor in term gravid women with cervical dilation 2 cm or less and intact membranes by using oral misoprostol preceded by transcervical Foley bulb placement results in a significantly increased vaginal delivery rate compared with the use of oral misoprostol alone. METHODS: We randomized the induction method by week of admission to labor and delivery, with each week group described as a cluster in a block randomized design. Women with gestational age of 37 weeks or greater, cervical dilation 2 cm or less, intact membranes, and indication for labor induction were included. Study arms were either 100 micrograms of oral misoprostol after transcervical Foley bulb placement or 100 micrograms of oral misoprostol alone. The primary outcome was vaginal delivery with the first induction attempt. Secondary outcomes included time to delivery, clinical chorioamnionitis (maternal temperature of 38°C or greater during labor with or without fundal tenderness, without other identified cause), cesarean delivery indication, and adverse outcomes. We estimated that a sample size of 1,077 per arm was needed to detect a 5% increase in vaginal delivery rate with a type I error of 5% and power of 80%, accounting for interim analysis and cluster size of 30 inductions per week. This was a pragmatic trial, and analysis was by intention-to-treat. RESULTS: From January 1, 2018, to May 13, 2019, 1,117 women (34 clusters) were assigned to oral misoprostol plus Foley and 1,110 women (34 clusters) to oral misoprostol alone. Demographic characteristics were similar. Vaginal delivery at the first induction occurred in 78% of the misoprostol plus Foley arm and in 77% of the misoprostol arm (relative risk [RR] 1.00; 95% CI 0.96-1.05; adjusted relative risk [aRR], 1.00; 95% CI 0.95-1.05). Clinical chorioamnionitis occurred in 18% of the misoprostol plus Foley arm and in 14% of the misoprostol arm (RR 1.30; 95% CI 1.07-1.58; aRR 1.30; 95% CI 1.08-1.56). There were no differences in neonatal outcomes. CONCLUSION: Induction of labor in gravid women at term with intact membranes by using oral misoprostol plus Foley bulb did not result in a higher vaginal delivery rate, but it did result in more clinical chorioamnionitis compared with the use of oral misoprostol alone. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03407625.
引用
- Adhikari EH, Nelson DB, McIntire DD, et al. Foley Bulb Added to an Oral Misoprostol Induction Protocol: A Cluster Randomized Trial. Obstet Gynecol. 2020. PMID: 33030881. doi:10.1097/AOG.0000000000004123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。